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Resumo
Com o advento do surfactante, dos corticosteróides 
pré-natais e dos avanços na tecnologia, a sobrevida dos 
recém-nascidos de extremo baixo peso tem melhorado 
dramaticamente. As taxas de displasia broncopulmonar 
(DBP) variam amplamente entre unidades, e vários es-
tudos, avaliando resultados de múltiplas intervenções, 
têm mostrado alguma melhoria na prevalência da DBP. 
A implementação de potenciais boas práticas na DBP 
tem sido adoptada por muitos serviços nas últimas dé-
cadas. Objectivo: Comparar cinco unidades portugue-
sas de cuidados intensivos neonatais no que se refere as 
práticas clínicas no tratamento dos recém-nascidos de 
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muito baixo peso, para desenvolver e melhorar as boas 
práticas na prevenção da DBP. População e métodos: 
Foram estudados 256 recém-nascidos com a idade ges-
tacional inferior a 30 semanas e/ou peso ao nascer infe-
rior a 1250 g, admitidos nas cinco unidades portugue-
sas (centros 1 a 5) entre 1 de Janeiro de 2004 e 31 de 
Dezembro de 2006. Foram excluídos os recém-nascidos 
com malformações major, hemorragia intraventricular 
grau IV na primeira semana de vida e com doença me-
tabólica ou neuromuscular. Definimos DBP como a 
dependência do oxigénio às 36 semanas de idade pós-
concepcional. A necessidade de melhorar determinada 
prática foi considerada significativa sempre que se veri-
ficava uma melhoria superior a 10% na prevalência da 
DBP ajustada para a prática, idade gestacional e peso ao 
nascer, comparada com a prevalência ajustada só para a 
idade gestacional e peso ao nascer. Resultados: A preva-
lência global da DBP foi de 12,9%. Os resultados mos-
tram que o uso de corticosteróides pré-natais deve ser 
melhorado nos centros 4 e 5; a política de fluidos deve 
ser melhorada no centro 4; o uso de oxigénio e a pre-
venção da sépsis deve ser melhorada nos centros 1 e 2. 
O tratamento do canal arterial patente deve ser melho-
rado no centro 2. Conclusão: Neste estudo, a imple-
mentação de boas práticas para reduzir a lesão pulmo-
nar nos recém-nascidos, de acordo com cada unidade, 
deve ser dirigida ao aumento da prescrição de corticos-
teróides pré-natais, ao uso de menor FiO2, ao uso crite-
rioso de líquidos na primeiras semanas de vida, à pre-
venção do canal arterial patente e da sépsis. Guidelines, 
recomendações ou protocolos são necessários na me-
lhoria da qualidade na prevenção da DBP. 
Rev Port Pneumol 2010; XVI (2): 273-286
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better practices to prevent BPD. Patients and meth-
ods: 256 preterm neonates, gestational age (GA) <30 
weeks and/or birthweight (BW) <1250g admitted to 
five Portuguese NICUs (centers 1 to 5) between 1st 
January 2004 and 31st December 2006, were studied. 
VLBW infants with major malformations, grade IV 
intraventricular haemorrhage in the first week of life 
and metabolic or neuromuscular disease were exclu-
ded. BPD was defined as oxygen dependency at 36 
weeks of postconceptional age. We considered a prac-
tice to be improved as clinically significant whenever 
a decrease greater than 10% in the prevalence of BPD 
adjusted for the practice, GA and BW was achieved 
compared to BPD prevalence adjusted only for GA 
and BW. Results: The overall prevalence of BPD was 
12.9%. Our results revealed that PNC use should be 
improved in centers 4 and 5; fluid policy in center 4; 
oxygen therapy and sepsis prevention in centers 1 and 
2. Patent ductus arteriosus (PDA) treatment should 
be improved in center 2. Conclusion: The imple-
mentation of potentially better practices to reduce 
lung injury in neonates in Portuguese NICUs, ac-
cording to each NICU, must be addressed to increase 
the prescription of PNC, to use a lower FiO2, to be 
careful with fluid administration in the first weeks of 
life and to prevent PDA and sepsis. It is necessary to 
follow guidelines, recommendations or protocols to 
improve quality in the prevention of BPD.
Rev Port Pneumol 2010; XVI (2): 273-286
Key-words: Bronchopulmonary dysplasia, neonatal 
intensive care, preterm infants, better practices, me-
chanical ventilation, oxygen therapy, prenatal corti-
costeroids, sepsis, patent ductus arteriosus.
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Introduction
Bronchopulmonary dysplasia (BPD) defini-
tion has changed since the first description 
of the disease by Northway et al. in 19671-5. 
The pathogenesis of BPD is clearly multi-
factorial and well-known specific pathoge-
nic risk factors include prematurity, respira-
tory distress syndrome (RDS), oxygen 
toxicity, barotrauma and volutrauma of me-
chanical ventilation (MV), inflammation 
and infection, excessive fluids and patent 
ductus arteriosus (PDA)6.
With the advent of surfactant, prenatal cor-
ticosteroids (PNC) and advances in tech-
nology, the survival rate of extremely low 
birth weight (ELBW) infants has improved 
dramatically. Despite these improvements 
the incidence of BPD in ELBW infants has 
remained stable over the last decades. Rates 
of BPD vary widely among NICUs and ac-
cording to gestational age. In a recent study, 
where BPD was defined as the need for oxy-
gen supplementation at 36 weeks postcon-
ceptional age (PCA), the incidence was 52% 
in infants with birth weight (BW) of 501-
750g, 34% in infants with BW 751-1000g, 
15% in infants with BW 1001-1200g and 
7% in infants with BW 1201-1500g5.
Several studies using multiple interventions 
have shown some improvement in BPD 
rates. However experience suggests that 
some of these interventions have not been 
effective when translated into clinical prac-
tice in neonatal intensive care units (NICUs). 
A large chasm between what we know and 
what we do has been reported in many areas 
of medicine, and seems to be true in the 
prevention of BPD as well7. Implementing 
potentially better practices to reduce BPD 
has been an effort made over the last few 
decades8-11.
The aim of our study was to evaluate and 
compare clinical practices in the manage-
ment of these very low birth weight (VLBW) 
newborns in five Portuguese NICUs in or-
der to develop better practices in the pre-
vention of BPD.
Patients and methods
VLBW infants with gestational age (GA) 
less than 30 weeks and/or BW less than 
1250 grams admitted to five Portuguese 
NICUs between 1st January 2004 and 31st 
December 2006 and alive at 36 weeks of 
PCA were included. VLBW infants with 
major malformations, grade IV intraven-
tricular haemorrhage (IVH) in the first 
week of life and metabolic or neuromuscu-
lar disease were excluded. A protocol was 
developed based on clinical information 
registered in the hospital charts: maternal 
history, prenatal corticosteroids, newborn 
demographical and clinical data, surfactant 
administration, ventilatory support, oxygen 
supplementation and fluid administration 
until 36 weeks of PCA. Neonatal sepsis, 
patent ductus arteriosus (PDA), necrotizing 
enterocolitis (NEC), retinopathy of prema-
turity (ROP), (IVH) and periventricular 
leukomalacia (PVL) were also registered.
BPD was defined as oxygen dependency at 
36 weeks of PCA and had characteristic chest 
radiographs12. Gestational age (in this study 
we considered the completed weeks) was as-
sessed by menstrual age (women with regu-
lar menstrual cycles), ultrasound exa mination 
(when a discrepancy of two or more weeks 
existed between the age derived by mens-
trual dating and the age derived sonographi-
cally, or in the absence of a menstrual date)13 
or the New Ballard Score (in the absence of 
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obstetrical indexes)14. RDS (hyaline mem-
brane disease (HMD)) was defined accord-
ing to the Rudolf AJ et al. criteria15. Proven 
neonatal sepsis was defined as any systemic 
bacterial or fungal infection documented by 
a positive blood culture. Hemodynamically 
significant PDA was diagnosed on the basis 
of the echocardiograph findings. The Bell 
criteria was used for the diagnosis and stag-
ing of NEC16. Staging of ROP was per-
formed according to the International Clas-
sification17,18. IVH was classified according 
to Papile LA19. PVL was classified according 
to de Vries L and Rennie JM20.
Chi-square (or Fisher´s Exact Test) and 
ANOVA were used, respectively, to com-
pare qualitative and quantitative variables 
among centers.
We considered a practice to be improved as 
clinically significant whether there was a de-
crease greater than 10% in the prevalence of 
BPD adjusted for the practice, compared to 
BPD prevalence adjusted only for GA and 
BW. The adjusted prevalence was estimated 
considering the mean for GA and BW and 
the practice in all centers.
The NICU with less prevalence of BPD was 
considered the reference center for estab-
lishing a comparison among the five cen-
ters. Odds ratios (OR) estimated by logisti-
cal regression and the respective 95% 
confidence intervals (95% CI) were used to 
measure the magnitude of the association 
between the centers and BPD. Statistical 
analysis was performed using the statistical 
package SPSS 17.0.
Results
A sample of 256 newborns met the inclusion 
criteria. The global prevalence of BPD was 
12.9% (33/256). The demographical charac-
teristics of the study population stratified by 
center are shown in Table I. We found statis-
tically significant differences among the five 
centers in BW, GA and HMD but not in sex. 
The clinical and therapeutical aspects of the 
study population stratified by center are 
shown in Table II. We did not find signifi-
cant differences among centers in surfactant 
ministration. Center 5 was considered the 
reference center for establishing the compari-
son among the five centers as it was the 
NICU with less BPD prevalence (2.7%), af-
ter adjusting for GA and BW (Table III). All 
centers used surfactant mainly as a rescue 
therapy rather than as a prophylactic treat-
ment. In Center 5, seven (9.9%) preterm in-
fants received prophylactic surfactant within 
15 minutes of birth (Tables II and III). Curo-
surf (poractant alpha) was used in Center 4 
and 5 in all newborns; in Centers 1, 2 and 3 
in 48%, 65% and 33%, respectively. Center 
3 used Survanta (beractant) in 67% of cases 
(p<0.001). The five centers revealed different 
practices concerning PNC, MV, oxygen 
therapy and fluids. The incidence of sepsis 
and PDA was also significantly different. The 
adjusted BPD by center, calculated assuming 
the mean of GA, BW of all sample and the 
mean prevalence of each clinical and thera-
peutical characteristic, is given in Table III. 
The prevalence of BPD adjusted for GA and 
BW varied from 13.5 % in Center 1 to 2.7 % 
in Center 5. Comparing the practices among 
NICUs, our results showed that PNC treat-
ment can be improved in Centers 4 and 5; 
fluid administration policy in Centers 4 and 
oxygen therapy in Centers 1 and 2; Centers 1 
and 2 can improve their policy of sepsis pre-
vention, and the Center 2 PDA prevention 
also (Table IV).
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We did not find significant differences 
among NICUs in surfactant treatment and 
MV practices (Tables II and III).
The major pathology (NEC, ROP, IVH, 
PVL) observed in our patients was signifi-
cantly different among the centers, ranging 
from 0% in Center 4 to 21.1% in Center 5. 
Centers 1, 2 and 3 registered 15.4, 7 and 
8.3% respectively of the cases (p=0.019).
Mortality rates by center in this group of 
Table I – Demographical and clinical characteristics of the study population stratifi ed by center
Center 1 Center 2 Center 3 Center 4 Center 5 p
N (%) 52 (20.3) 58 (22.7) 58 (22.7) 48 (18.8) 27 (10.9) 71 (27.7)
Birth weight (grams)
Mean ± SD   1030±230 1040±240 1220±240 1000±220 1030±260 <0.001
Gestational age (weeks) 
Mean ± SD 28.5±2.1 28.2±2.0 28.8±1.1 27.6±2.0 27.8±2.0 <0.001
Sex (% female) 44.2 46.6 58.3 44.4 57.7 0.380
HMD* (%) 66.7 50 73.6 65.7 56 0.036
* Hyaline membrane disease moderate and severe
Table II – Clinical and therapeutical aspects stratifi ed by center
Center 1 Center 2 Center 3 Center 4 Center 5 pn (%) n (%) n (%) n (%) n (%)
Prenatal corticosteroids
No treatment 7 (13.5) 6 (10.7) 1 (2.1) 5 (18.5) 17 (23.9) 0.015
Incomplete treatment 16 (30.8) 11 (19.6) 14 (29.2) 10 (37) 23 (32.4)
Complete treatment 29 (55.8) 39 (69.6) 33 (68.8) 12 (44.4) 31 (43.7)
Surfactant
No surfactant 21 (40.4) 13 (22.8) 16 (33.3) 8 (29.6) 16 (22.5) 0.059
Prophylactic 1(1.9) 0 (0) 2 (4.2) 0 (0) 7 (9.9)
Rescue 30 (57,7) 44 (77.2) 30 (62.5) 19 (70.4) 48 (67.6)
Fluids 1st week, (ml/kg) (X±SD) 120 (7) 117 (12) 107 (10) 128 (11) 108 (9) <0.01
Mechanical ventilation
No ventilation 2 (3.8) 5 (8.6) 9 (18.8) 3 (11.1) 1 (1.4) 0.022
N-CPAP 12 (23.1) 8 (13.8) 6 (12.5) 2 (7.4) 16 (22.5)
Invasive ventilation 38 (73.1) 45 (77.6) 33 (68.8) 22 (81.5) 54 (76.1)
FiO2
0-0.39 16 (32.7) 15 (26.8) 35 (79.5) 10 (38.5) 47 (74.6) <0.001
≥0.40 33 (67.3) 41 (73.2) 9 (20.5) 16 (61.5) 16 (25.4)
Sepsis
No 12 (23.1) 25 (43.1) 34 (70.8) 18 (66.7) 48 (67.6) <0.001
Yes 40 (76.9) 30 (56.9) 13 (29.2) 9 (33.3) 23 (32.4)
Patent ductus arteriosus
No 39 (75) 33 (56.9) 34 (70.8) 24 (88.9) 49 (69) 0.041
Yes 13 (25) 25 (43.1) 14 (29.2) 3 (11.1) 22 (31)
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preterm newborns were 18% in Center 1, 
24% in Center 2, 19% in Center 3, 10% in 
Center 4 and 19% in Center 5.
Discussion
Despite increased knowledge and improving 
technology, BPD rates remain high. Its inci-
dence varies among institutions, ranging 
from 15 to 50% of all VLBW infants21. 
These differences could be due in part to the 
definition of BPD and to the decision to ad-
minister oxygen that is not uniform, as there 
is no consensus in the literature and neona-
tologists have widely divergent practices re-
garding oxygen saturations targets. In this 
study we used the BPD definition of oxygen 
dependency at 36 weeks of PCA and the 
Table III – Adjusted prevalences of bronchopulmonary dysplasia by center calculated assuming the mean of gestational age, 
birth weight of all sample and the mean prevalence of each clinical characteristic
Center 1 Center 2 Center 3 Center 4 Center 5
BPD (%) 21.2 17.2 6.2 11.1 8.5
OR crude 2.9 (1.0-8.5) 2.2 (0.8-6.6) 0.7 (0.2-3.0) 1.4 (0.3-5.8) 1
BPD (%) 13.5 9.9 8.9 3.4 2.7
OR* 5.6 (1.6-19.5) 3.9 (1.1-13.3) 3.5 (0.7-18.2) 1.3 (0.13-6.3) 1
BPD (%) 12.5 8.6 9 2.7 2.2
OR* and adjusted for PNC (95% CI) 6.3 (1.7-23.1) 4.1 (1.1-15.2) 4.3 (0.8-24.2) 1.2 (0.2-6.1) 1
BPD (%) 13.3 9 8.1 3.3 2.6
OR* and adjusted for Surf (95% CI) 5.7 (1.6-20.0) 3.6 (1.0-12.8) 3.3 (0.6-17.4) 1.3 (0.3-6.4) 1
BPD (%) 13.5 10.7 5.7 5.3 2.1
OR* and adjusted for Fluids (95% CI) 7.4 (1.6-34.9) 5.7 (1.2-26.4) 2.9 (0.4-19.4) 2.7 (0.3-22.4) 1
BPD (%) 13 9.2 8.2 3.2 2.6
OR* and adjusted for MV (95% CI) 5.5 (1.6-19.6) 3.8 (1.1-13.0) 3.3 (0.6-18.1) 1.4 (0.3-7.1) 1
BPD (%) 11.4 10.2 7.3 3.6 3.1
OR* and adjusted for FiO2 (95% CI) 4.1 (0.9-17.8) 3.6 (0.8-15.6) 2.5 (0.4-16.5) 1.2 (0.2-6.8) 1
BPD (%) 8.4 7.8 8.6 3.7 2.7
OR* and adjusted for Sepsis (95% CI) 3.2 (0.9-12.1) 3 (0.8-10.2) 3.3 (0.6-17.9) 1.2 (0.3-6.1) 1
BPD (%) 13 8.4 8.3 4.1 2.7
OR* and adjusted for PDA (95% CI) 5.3 (1.5-18.8) 3.2 (0.4-11.4) 3.2 (0.6-17.2) 1.5 (0.3-7.6) 1
OR – odds ratio; OR* – adjusted for gestational age and birth weight
Surf – surfactant; MV – mechanical ventilation; PDA – patent ductus arteriosus; PNC – prenatal corticosteroids
Table IV – Practices to be improved by center (+)
Center 1 Center 2 Center 3 Center 4 Center 5
Prenatal corticosteroids + +
Fluids +
FiO2 + +
Sepsis + +
Patent ductus arteriosus +
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prevalence of BPD ranged from 13.5% in 
Center 1 to 2.7% in Center 5. To decrease 
the significant differences, efforts must be 
made to identify infants treated with oxygen 
who are able to maintain saturations exceed-
ing 90% in room air4,22. Another aspect 
which may explain these differences in the 
prevalence of BPD is the management of 
these preterm infants. After four decades 
since the original description by Northway, 
its clinical presentation, evidence as to its 
pathogenesis and epidemiology has changed, 
and the understanding of this process has 
provided new possibilities for BPD preven-
tion. As BPD is a multifactorial disease, a 
multifaceted approach to the management 
of preterm infants is necessary to prevent it. 
Knowing that BPD rates differ greatly 
among centers we analysed and compared 
practices in five centers to develop and im-
plement potentially better practices to re-
duce BPD, as has been done over the last 
few decades in many other centers.
Prenatal corticosteroids – RDS is a serious 
complication of preterm birth and the pri-
mary cause of early neonatal mortality and 
disability that has been reduced by adminis-
tering corticosteroids to the mother before 
anticipated preterm birth23,24.
In spite of the beneficial effect PNC has on 
foetal pulmonary maturity, we found sig-
nificant differences among the five NICUs 
of the study. As shown in Table II, in Center 
5, 23.9% of the mothers did not receive 
PNC and in Center 3, 68.8% received a full 
course. Centers 4 and 5 decreased the BPD 
rate when adjusted to BW, GA and the 
mean of this practice of all centers. This 
means that they must improve PNC treat-
ment in order to reduce their BPD rate 
(Tables III and IV).
The evidence supports the continued use of 
a single vs. multiple course of PNC to ac-
celerate foetal lung maturation in women at 
risk of preterm birth, with a single course 
considered routine for preterm delivery23-26.
Repeated doses of PNC reduce the occur-
rence and severity of neonatal lung disease 
and the risk of serious health problems in the 
first few weeks of life. These short-term be-
nefits for babies support the use of repeat 
doses of PNC for women at risk of preterm 
birth. However, these benefits are associated 
with a reduction in some measures of weight 
and head circumference at birth, and there is 
still insufficient evidence on the longer-term 
benefits and risks. National Institutes of 
Health recently recommended that no more 
than one course of PNC be used routinely 
outside clinical trials25. In this study all mo-
thers treated with PNC received only a single 
course (complete or incomplete) of PNC.
Surfactant – Exogenous surfactant therapy to 
prevent or to treat HMD in premature infants 
clearly reduced neonatal mortality and sur-
vival without BPD27. Although some studies 
show that treatment with exogenous surfac-
tant may decrease the incidence or severity of 
BPD, the fact is that surfactant use has not 
clearly reduced the incidence of BPD28. This 
may be due, in part, to its effect on improving 
survival of extremely immature infants who 
would have died without surfactant therapy.
We also know that oxidant injury and lung in-
flammation in extremely premature infants are 
associated with the development of BPD. Sur-
factant dysfunction resulting from these events 
may also contribute to the pathogenesis of 
BPD, justifying exogenous surfactant treatment 
to decrease inflammation and improve RDS29.
Nowadays exogenous surfactant is used 
worldwide in neonatal intensive care27-34.
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Early surfactant replacement therapy with 
extubation to nasal continuous positive air-
way pressure (N-CPAP) compared with 
later selective surfactant replacement and 
continued mechanical ventilation with ex-
tubation from low ventilator support has 
been shown to be associated with less need 
for MV, lower incidence of BPD and fewer 
air leak syndromes30.
Evidence has shown a benefit to multiple ver-
sus single doses of exogenous surfactant in the 
prevention or treatment of neonatal RDS31.
In Portugal, about 50% of VLBW infants 
have received surfactant for RDS since 
1996, and a schedule of multiple doses has 
been adopted33.
In this study we did not find any difference 
among centers in surfactant administration. 
All centers used surfactant mainly as a res-
cue rather than a prophylactic therapy. We 
know that early rescue (<30 minutes of age) 
surfactant therapy is an effective method to 
minimize overtreatment of some preterm 
infants who may not develop RDS32. Ne-
vertheless, in Center 5, seven (9.9%) pre-
term infants received prophylactic surfac-
tant (Tables II and III).
Recently, the results of eight prospective, 
randomized controlled trials and two retros-
pective studies involving the natural surfac-
tant preparations, treatment with poractant 
alpha revealed a significant decreased in 
mortality, decreased need for additional 
doses, faster weaning from oxygen and re-
duced hospital costs than treatment with 
beractant or calfactant. These differences in 
outcome may be due to differences in phos-
pholipid and SP-B content and the amount 
of antioxidant phospholipids, plasmalogens, 
anti-inflammatory properties and viscosity 
among these three surfactants34.
The result of this large trial may explain the 
choice of Curosurf (poractant alpha) as the 
most used surfactant in four centers and 
only Center 3 used Survanta (beractant) in 
a higher percentage (67% of cases). Another 
reason for this choice is the small volume of 
Curosurf needed to treat these extremely 
preterm infants.
Fluids – Excessive fluid intake and/or de-
layed weight loss and prolonged PDA are 
well-known major pathogenic mechanisms 
for BPD. Infants with BPD have increased 
lung water and are susceptible to gravity-
induced collapse and alveolar flooding in 
the dependent lung with focal tissue da-
mage being distributed heterogenously. 
High fluid volumes in the first days of life 
may increase neonatal morbidity and is as-
sociated to increased risk of PDA. Therefore 
fluid restriction, with the goal of reducing 
BPD risk, is standard treatment in the care 
of the premature infant10,35,36.
Comparing fluid administration among 
the five centers showed significant diffe-
rences. This study showed that this practice 
can be improved in Center 4, as we can see 
when adjusted to the mean of this practice 
in all centers (Tables III and IV). Attention 
must be paid to decrease fluids in the first 
weeks of life, allowing physiological weight 
loss in these very immature preterm infants. 
However, evidence supporting fluid restric-
tion is inconclusive and we must remember 
that restricting fluids may also restrict calo-
rie intake37.
Mechanical ventilation – Invasive ventilation 
via the endotracheal tube is one of the most 
common therapeutic interventions per-
formed in preterm infants with respiratory 
failure. MV ventilation using conventional 
or high-frequency ventilation and surfactant 
Displasia broncopulmonar: práticas clínicas em cinco unidades 
de cuidados intensivos neonatais
H Guimarães, G Rocha, G Vasconcellos, E Proença, ML Carreira, MR Sossai, B Morais, I Martins, T Rodrigues, M Severo
R e v i s t a  P o r t u g u e s a  d e  P n e u m o l o g i a 281
Vol XVI  N.º 2  Março/Abril  2010
therapy has become the standard of care in 
management of preterm infants with RDS. 
However, BPD remains a major morbidity 
with adverse pulmonary and nonpulmonary 
outcomes in preterm infants despite these in-
terventions. Ventilator-associated lung injury 
appears to be related to the duration of inva-
sive ventilation via the endotracheal tube 
rather than the mode of ventilation. Ran-
domized controlled trials comparing conven-
tional mechanical ventilation and high-fre-
quency ventilation, using ‘optimal ventilatory 
strategies’, have shown no significant diffe-
rence in rates of BPD. Use of noninvasive 
ventilation, such as N-CPAP, has shown a 
significant decrease in postextubation failure 
as well as reduced incidence of BPD10,38-40.
In this study we found no significant diffe-
rence in mechanical ventilation among centers 
(Table III). In Center 3, 18.8% of preterm in-
fants were not ventilated, which could be due 
to the fact that they were heavier than in the 
other four centers. N-CPAP was used in Cen-
ter 1 and 5, respectively in 23.1% and 22.5%. 
Invasive ventilation (SIPPV=synchronized in-
termittent positive pressure ventilation; 
SIMV=synchronized intermittent mandatory 
ventilation; HFOV=high frequency oscillato-
ry ventilation) was used in 81.5% of cases in 
Center 4, and in other Centers ranged from 
68.8% in Center 3 and 77.6% in Center 2.
N-CPAP or early surfactant therapy with 
early extubation to N-CPAP rather than 
continued mechanical ventilation has been 
adopted by many centres, particularly in 
Scandinavia, as part of the treatment of 
newborns with RDS. It has been suggested 
that BPD is less of a problem in centres 
adopting such a policy. Results from ran-
domized trials suggest prophylactic or early 
N-CPAP may reduce BPD, but further 
studies are required to determine the rela-
tive contributions of an early lung recruit-
ment policy, early surfactant administration 
and N-CPAP in reducing BPD. In addi-
tion, the optimum method of generating 
and delivering N-CPAP needs to be deter-
mined. The efficacy of N-CPAP in improv-
ing long-term respiratory outcomes needs 
to be compared with the newer ventilator 
techniques and the optimum timing of de-
livery of surfactant administration41.
In Portugal efforts have been made to begin 
an optimal ventilatory strategy in the deli-
very room in preterm infants with RDS 
with application of sustained inflation to es-
tablish functional residual capacity (N-
CPAP), followed by early surfactant therapy 
if needed and extubation as soon as possible 
to noninvasive ventilation. After the Portu-
guese Consensus on newborn management 
in the delivery room published in 2004, 
most NICUs standardised their practices. 
This is probably the reason why we did not 
find significant differences among centers 
in respiratory support strategies.
Oxygen – Oxygen is the most commonly 
used therapy in NICUs as an integral part 
of respiratory support. The objective of oxy-
gen therapy is to achieve adequate delivery 
of oxygen to the tissues without creating 
oxygen toxicity. However current evidence 
for optimal oxygen saturation for extremely 
premature infants is scarce. We still know 
very little about how much oxygen these ba-
bies actually need, or how much oxygen it is 
safe to give, especially in the first few weeks 
of life41-44.
Avoiding hyperoxemia is an important goal 
during respiratory support and neonatal ex-
posure to 100% oxygen is almost never ne-
cessary. Much lower fraction of inspired 
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oxygen (FiO2) during the neonatal period 
can also lead to oxygen toxicity if oxygen is 
used when it is not necessary. Even brief 
neonatal exposure to pure oxygen must be 
avoided45.
In the STOP-ROP trial (supplemental ther-
apeutic oxygen for prethreshold retinopa-
thy), babies in the supplemental oxygen arm 
(target saturations of 96-99%) had evidence 
of adverse pulmonary outcome compared 
to those in the conventional oxygen arm 
(target saturations of 89-94%)46.
The recent studies of Saugstad and co-
workers showed that oxygen saturations le-
vels in ELBW infants should be kept be-
tween 85 and 93% or possibly between 88 
and 95%, but should definitely not exceed 
95% and fluctuations should be avoided44.
Recent data show that a lower FiO2, less 
than 0.45, confers greater advantage in re-
ducing the incidences of air leak syndromes 
and BPD compared to a higher FIO2 (more 
than 0.45), in the treatment of RDS30.
In our study, Centers 3, 4 and 5 appear to 
have more accurate FiO2 administration 
practices and oxygen therapy should be im-
proved in Centers 1 and 2 (Tables III and 
IV). Although evidence for BPD protection 
by reducing oxygen exposure is not well 
demonstrated, we know the toxicity of oxy-
gen and its free radicals, and better practices 
in oxygen supplementation must be imple-
mented in our NICUs11,47.
Sepsis – Inflammation (and infection), ei-
ther antenatal or postnatal, is likely to be a 
major trigger for the lung inflammation 
that plays a role in the pathogenesis of 
BPD6,48,49.
Although there is recent evidence that pre-
mature infants born to mothers with cho-
rioamnionitis are at increased risk of deve-
loping BPD48,50, other studies were unable 
to confirm this association51. In this study 
the association between histological chorioa-
mnionitis and BPD was not analysed because 
placental histological data were missing.
The presence of nosocomial infections dur-
ing the first month of life increases the risk 
of BPD in preterm infants requiring pro-
longed mechanical ventilation, another risk 
factor for the disease52,53.
In our study, early and late or nosocomial in-
fections were included in the group of sepsis, 
because of the small numbers of cases in each 
center. Neonatal sepsis was observed in all 
centers with a significant prevalence that 
ranged from 29.2 to 76.9% (Table II). Cen-
ters 1 and 2 registered higher rates of sepsis, 
which were higher than the national average 
of 35%33. Rates of early– and late-onset septi-
caemia of 5 and 29.4% respectively in VLBW 
infants have recently been published54.
As we can see in these two centers (Centers 
1 and 2) must improve their policy of sepsis 
prevention to decrease the rate of BPD (Ta-
bles III and IV).
It is crucial to reduce neonatal sepsis in our 
preterm infants in all NICUs, as even in 
centers with a low rate of sepsis we can lower 
the BPD rate still further.
Patent ductus arteriosus – The most com-
mon congenital heart disease in the new-
born population, PDA, accounts for signifi-
cant morbidity in preterm newborns. With 
the increasing survival of extremely prema-
ture infants, a large number of them are de-
veloping chronic lung disease, but the seve-
rity of the lung damage is considerably less 
than that observed in the classic form of 
BPD. Because many of these infants have 
only a mild initial respiratory distress and 
therefore do not receive aggressive ventila-
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tion, it is clear that factors other than oxy-
gen toxicity and mechanical ventilation are 
involved in the pathogenesis of this new 
milder type of BPD6,52.
In this study an 11.1%,rate of PDA was ob-
served in Center 4, and a rate of 43.1% in 
Center 2. These percentages differ from the 
rate of PDA in VLBW infants in Portugal 
that was 20% in a five-year study (1996-
2000)33. These differences may be due to 
the method used for diagnosis that is mostly 
clinical but should be confirmed by Dop-
pler ultrasound.
Center 2 can improve practices on preven-
tion of PDA, as when we adjusted the BPD 
rate to the mean of practices of all centers 
the BPD rate decreased from 9.9 to 8.4%, 
more than the 10% defined as significant 
(Tables III and IV).
Clinical and epidemiological data strongly 
suggest that the presence of PDA plays a 
major role in the development of BPD in 
these infants. For this reason, efforts to pre-
vent BPD in ELBW infants should include 
an aggressive approach to an early closure of 
the hemodynamically significant PDA55-58. 
However it has also been assessed that in 
randomized controlled trials, neither a sig-
nificant reduction, nor even a trend towards 
a reduction on BPD was observed47.
Major pathology – In major pathology we 
included NEC (> grade IIA), ROP (> grade 
3), IVH (grades III-IV) and PVL. The ma-
jor pathology observed was significantly dif-
ferent among the centers. Centers 1, 2, 3, 4 
and 5 registered 15.4, 7, 8.3, 0 and 21.1% 
of major pathology respectively (p=0.019).
In Center 5 we observed a major pathology 
prevalence of 21.1% and in Center 4 no 
cases of major pathology were registered. 
Nonetheless, Center 4 contributed with the 
most immature babies. This fact can be due 
in part to the transfer to other NICUs of 
preterms with major complications that 
needed special treatment, namely neurolo-
gical, ophthalmological or digestive surgery.
Center 1 and Center 5 are NICUs with sur-
gery facilities, which can, in part, explain 
the higher prevalence of major pathology of 
15.4 and 21.1% respectively of the cases.
In a previous study in Portugal including 
VLBW infants, we found IVH in 27%, 
NEC in 10%, ROP in 9%, PVL in 6%, of 
preterm infants less than 1500g33.
In a recent Spanish study, intraventricular 
haemorrhage grades III to IV (8.1%) and 
cystic leukomalacia (2.6%) were the most 
relevant brain ultrasound findings and NEC 
was observed in 6.9% of VLBW infants54.
In a ten-year period investigating trends in 
mortality and morbidity in very preterm infants 
there were no changes in the rates of IVH 
(grades III-IV), ROP (grades > 3), seizures or 
NEC. The increasing rate of sepsis was present 
in infants <28 gestational weeks, whereas the 
increase in BPD was demons trated in the whole 
study population <32 gestational weeks59.
The mortality rates observed in this group 
of preterm newborns in the five NICUs of 
the study varied from 10% in Center 4 to 
24% in Center 2. The differences can be ex-
plained, in part, by the same fact that also 
explains the low prevalence of major patho-
logy, the transfer of the preterm infants that 
needed surgery. However it was observed 
that Center 3 is the center that showed less 
practices to be improved (Table IV).
Conclusion
Bronchopulmonary dysplasia is one of the 
most common long-term complications in 
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very premature infants. Its incidence has 
been increasing over the past two decades in 
parallel with an improvement in the survival 
of this population.
BPD results from the interaction of multi-
ple factors that can injure the immature 
lung. For this reason prevention must be 
based on the elimination of all the factors 
implicated in its pathogenesis.
The significant differences in BPD preva-
lence observed among centers, reflecting 
different practices in the management of 
ELBW infants, suggest that efforts must be 
put into developing and adopting better 
practices in BPD prevention.
The implementation of potentially better 
practices to reduce lung injury in neonates 
in Portuguese NICUs according to each 
NICU, must be addressed to increase the 
prescription of PNC, to use a lower FiO2, 
to be careful with fluid administration in 
the first weeks of life and to prevent PDA 
and sepsis.
Guidelines, recommendations or protocols 
must be followed to improve quality in the 
prevention of BPD.
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